KANGHUI PHARMACEUTICAL(SH:603139)2026-01-23 08:00Financial Performance - The company expects a net loss of approximately ¥327 million for the fiscal year 2025, attributed to various factors including operational challenges [2]. - The estimated net profit attributable to the parent company, excluding non-recurring gains and losses, is projected to be around ¥208 million in loss [4]. - The previous year's net profit attributable to the parent company was a loss of ¥89.63 million, with a total profit of -¥121.54 million [5]. Reasons for Loss - The primary reason for the anticipated loss is the shutdown of the subsidiary Shaanxi Youbang Biopharmaceutical Technology Co., which has led to a bad debt provision impacting the company's performance by approximately ¥125 million [7]. - The subsidiary's asset impairment, based on an evaluation, is expected to affect the net profit by about ¥87 million, contributing to a total impact of approximately ¥114 million on the company's performance [7]. Sales and Operational Challenges - The company's sales revenue has slightly declined due to changes in the pharmaceutical industry policies and macroeconomic conditions, prompting adjustments in sales strategies [7]. - The company is increasing investments in channel and brand development to counteract the decline in sales revenue [7]. - The operational costs remain high due to the simultaneous operation of new and old production bases during the product transition phase [7]. Financial Reporting - The financial data provided is preliminary and subject to change upon the completion of the official audited annual report for 2025 [9]. - The company assures that there are no significant uncertainties affecting the accuracy of this earnings forecast [8].